Meso Scale Discovery (MSD) is a proprietary technology for measuring analytes in complex biological samples. With assay options such as MesoScale cytokine multiplex assays, scientists can profile cytokines and other intracellular signaling proteins, directly impacting drug discovery and development. MSD assays are similar to ELISA, but they employ electrochemiluminescence detection compared to colorimetric reaction in ELISA assays.
MSD ELISA assay combines electrochemiluminescence detection with multi-array technology to provide multiplex functionality and unsurpassed sensitivity. MSD ELISA electrochemiluminescence detection is a unique combination of broader dynamic range, sensitivity, and convenience. Meso Scale ELISA systems can deliver high-quality and reliable data in different sample types such as blood, serum, plasma, cell lysates, tissue homogenates, urine, etc.
Multi-array strategies offer highly dense and rapid information during biological analysis. This feature, combined with multi-spot plates, enables the quantification of multiple analytes in a single assay volume, ultimately reducing the efforts, time, and sample required for biological analysis. Hence, ELISA Lab and other immunoassay services are relying increasingly on MSD ELISA assays for tracking pathogens and immune responses. The current article discusses the reason why MSD assay services are used increasingly in infectious disease research.
MSD ELISA assay for tracking pathogens and immune responses
MSD platforms have R-plex serology panels specifically for infectious disease research. These panels can detect antibodies against antigens from SARS-CoV-2 and its variants, MERS, SARS-1, circulating coronavirus, and other respiratory pathogens. This panel consists of large libraries of antigens. Notably, R-plex serology panels include the SARS-CoV-2 panel, which was the panel of choice for assessing phase 3 clinical trial coronavirus vaccines.
The V-plex SARS-CoV-2 serology panel identifies antigens, including the alpha, beta, gamma, delta, lambda, mu, and omicron variants. Besides, the V-plex respiratory panels include antigens for RSV and influenza. The MSD serology panels have kits to measure antibodies of the SARS-CoV-2 virus, which is a high throughput alternative to conventional neutralizing antibody assays.
All MSD human serology tests come in complete kits with reference standards and controls. The reference standard-1 in the serologic tests is calibrated with WHO international standards, while the results can be reported in international units.
MSD offers COVID-19 samples as test samples in serology kits. This test sample contains human serum with antibodies against antigens from SARS-CoV-2, circulating coronavirus, SARS-1, and other respiratory pathogens. Each antibody concentration has assigned values, and hence, scientists can use them to assess their experimental performance. Moreover, these test samples are available as individual samples or in panels.
When it comes to biomarker and antigen assays, MSD has two formats: direct detection S-plex and R-plex. S-plex kits measure the nuclear capsid antigens and spike protein with ultra-sensitive detection. On the other hand, R-plex antibody sets can help researchers develop single and multiplex assays while including different combinations of biomarkers. Not to mention, MSD has different panels for biomarkers, including cytokines and other analytes relevant to infectious diseases.
Therefore, MSD ELISA assays are an ideal platform for tracking pathogen responses in infectious disease research.